Is avatrombopag (Sucoxin) a hormonal drug and its differences

Avatrombopag (Avatrombopag) is an oral small molecule thrombopoietin receptor agonist (TPO-RA), mainly used to treat chronic liver disease or thrombocytopenia caused by specific diseases. It activates the differentiation and maturation of megakaryocytes in the bone marrow by simulating the effect of endogenous thrombopoietin (TPO), thereby increasing the number of platelets. It should be clear that avatrombopag is not a hormonal drug and its mechanism of action is completely different from that of glucocorticoids or other steroid drugs.

Hormonal drugs, such as prednisone or methylprednisolone, mainly treat thrombocytopenia by regulating the immune system and inflammatory response, and are often used for diseases such as immune thrombocytopenic purpura (ITP). Hormones indirectly increase platelet levels by suppressing autoimmune attacks, but may be accompanied by side effects such as immune suppression, increased blood sugar, and water and sodium retention. Avatrombopag, on the other hand, directly stimulates platelet production and fundamentally increases the number of platelets. It has no immunosuppressive effect, so the side effect spectrum is significantly different.

Clinically, avatropopag is indicated for thrombocytopenic intervention in patients with chronic liver disease before undergoing invasive procedures, and for long-term maintenance treatment of chronic immune thrombocytopenia. In contrast, hormonal drugs are mostly used for short-term control of acute thrombocytopenia or inflammatory diseases. The effects of avatrombopag are more targeted and predictable, and are better tolerated with long-term use, whereas long-term use of hormones may lead to an increased risk of osteoporosis, diabetes, or infection.

Therefore, when selecting a treatment option, the decision to use avatrombopag or hormonal drugs should be based on the type of disease, the cause of platelet decline, and the patient's tolerance. The advantage of avatrombopag is that it can directly increase platelets without immunosuppression, making it suitable for patients with poor sensitivity or intolerance to hormones. During medication, platelet levels and liver function should be monitored regularly to ensure efficacy and safety. Overall, there are obvious differences between avatrombopag and hormonal drugs in terms of mechanism of action, indications and safety. It is a non-hormonal and more targeted platelet production drug.

Reference materials:https://www.drugs.com/